The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination

ObjectivesThe Belgian population of people living with HIV (PLHIV) has unrestricted access to direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection, since 2017. International literature claims that half the patients remain untreated in high-income countries DAA. This study was initiated provide an overview present situation Belgium and recommendations HCV care PLHIV other regions.MethodsThis a retrospective, multicenter Belgium, from January 1, 2007 December 31, 2018. The cascade examined.ResultsOut 4607 unique PLHIV, 322 (7.0%) tested positive antibody RNA positivity seen 289 (6.3%). Of those proven 207/289 (71.6%) treatment. 171 (82.6%) persons sustained virologic response (SVR), 16 (9.4%) subjects were reinfected.ConclusionsWe Belgium. Treatment initiation SVR rates high compared regions. Implementation national register track progress yearly screening, especially high-risk behavior, remains crucial. Identifying reasons not initiating is necessary achieve elimination by 2030.